Search results
Results from the WOW.Com Content Network
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB.. The medical standard for active TB is a short course treatment involving a combination of isoniazid, rifampicin (also known as Rifampin), pyrazinamide, and ethambutol for the first two months.
Ethionamide is a prodrug [17] which is activated by the enzyme ethA, a mono-oxygenase in Mycobacterium tuberculosis, and then binds NAD+ to form an adduct which inhibits InhA in the same way as isoniazid. The mechanism of action is thought to be through disruption of mycolic acid. [5] [18]
Delamanid is sold under the brand name Deltyba, is a medication used to treat tuberculosis. [2] Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. [2] It is taken by mouth. [2] There are common side effects which include headache, dizziness, and nausea. [3]
Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. [4] For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. [5] For latent tuberculosis, it is often used alone. [4]
(S,S)-(+)-Ethambutol is powerful and selective antitubercular drug.It is a typical example of an old drug that was introduced for clinical use in its unichiral form. . Ethambutol contains two constitutionally symmetrical chiral centers in its structure and exists in three stereoisomeric forms, the enantiomeric pair (+)-(S,S)- and (−)-(R,R)-ethambutol, along with the achiral stereoisomer called m
T-SPOT.TB counts the number of antimycobacterial effector T cells, white blood cells that produce interferon-gamma, in a sample of blood.This gives an overall measurement of the host immune response against mycobacteria, which can reveal the presence of infection with Mycobacterium tuberculosis, the causative agent of tuberculosis (TB).
Pretomanid is only the third tuberculosis drug to receive approval from the FDA in more than 40 years. [4] [9] The FDA granted pretomanid priority review and orphan drug designations. [4] The FDA granted The Global Alliance for TB Drug Development (TB Alliance) the approval of pretomanid and a tropical disease priority review voucher. [4]
In December 2010, the World Health Organization (WHO) endorsed the Xpert MTB/RIF for use in tuberculosis (TB) endemic countries. [3] The announcement followed 18 months of assessing its field effectiveness in tuberculosis, MDR-TB, and TB/HIV co-infection. [4] The test may enable the diagnosis of TB in patients likely to be missed by traditional ...